Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia

J Clin Oncol. 2013 Jul 1;31(19):e300-3. doi: 10.1200/JCO.2012.45.9495. Epub 2013 May 20.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cladribine / administration & dosage
  • Drug Resistance, Neoplasm
  • Flow Cytometry
  • Glutamic Acid
  • Humans
  • Indoles / administration & dosage
  • Indoles / adverse effects
  • Indoles / pharmacology*
  • Indoles / therapeutic use*
  • Induction Chemotherapy
  • Leukemia, Hairy Cell / diagnosis
  • Leukemia, Hairy Cell / drug therapy*
  • Leukemia, Hairy Cell / genetics*
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Point Mutation*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics
  • Rituximab
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use*
  • Treatment Outcome
  • Valine
  • Vemurafenib

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Indoles
  • Sulfonamides
  • Vemurafenib
  • Glutamic Acid
  • Cladribine
  • Rituximab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Valine